<DOC>
	<DOC>NCT01601119</DOC>
	<brief_summary>The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).</brief_summary>
	<brief_title>Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Relapsing Multiple Sclerosis patients aged 18 years or over. Naive to previous DMT therapy and not yet started treatment with a disease modifying therapy. Participating in an MSrelated clinical trial. Unwilling to provide electronic online consent. Any disability that may impair them from being able to complete the online questionnaire. Do not have regular access to the Internet. Unable to complete the baseline questionnaire before they receive their first DMT injection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Patient reported outcome</keyword>
	<keyword>Patient reported experience</keyword>
</DOC>